A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator ’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck

ConclusionsIn CheckMate 141, nivolumab resulted in statistically significant and clinically meaningful gains (relative difference  >  10%) in quality-adjusted survival vs standard of care in patients with R/M SCCHN.
Source: PharmacoEconomics - Category: Health Management Source Type: research